Objective: To evaluate the associations between 10 well-established ovarian cancer risk factors and risk of ovarian cancer among women with vs. without endometriosis.

Design: Pooled analysis of 9 case-control studies in the Ovarian Cancer Association Consortium.

Setting: Population-based.

Patient(s): We included 8,500 women with ovarian cancer, 13,592 control women.

Intervention(s): Ten well-established ovarian cancer risk factors.

Main Outcome Measure(s): Risk of ovarian cancer for women with and without endometriosis.

Result(s): Most risk factor-ovarian cancer associations were similar when comparing women with and without endometriosis, and no interactions were statistically significant. However, body mass index (BMI) 25-<30 kg/m was associated with increased ovarian cancer risk among women with endometriosis (odds ratio [OR] = 1.27, 95% confidence interval [CI] 1.00-1.60), but not associated with the risk among women without endometriosis (OR = 0.97; 95% CI, 0.91-1.05) when compared with BMI 18.5-<25 kg/m; an increased risk was observed for a BMI ≥30 kg/m, although there was little difference comparing women with endometriosis (OR = 1.21; 95% CI, 0.94-1.57) to women without (OR = 1.13; 95% CI, 1.04-1.22) (P-interaction = .51). Genital talcum powder use and long-term menopausal estrogen-only therapy use showed increased ovarian cancer risk, but risk appeared greater for those with endometriosis vs. those without (genital talcum powder: OR = 1.38; 95% CI, 1.04-1.84 vs. OR = 1.12; 95% CI, 1.01-1.25, respectively; ≥10 years of estrogen-only therapy: OR = 1.88; 95% CI, 1.09-3.24 vs. OR = 1.42; 95% CI, 1.14-1.76, respectively); neither of these interactions were statistically significant (P-interaction = .65 and P-interaction = .96, respectively).

Conclusion(s): The associations between ovarian cancer and most risk factors were similar among women with and without endometriosis. However, there was some suggestion of differences by endometriosis status for BMI, menopausal hormone therapy use, and genital talcum powder use, highlighting the complexity of ovarian cancer etiology.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9969849PMC
http://dx.doi.org/10.1016/j.fertnstert.2022.07.019DOI Listing

Publication Analysis

Top Keywords

ovarian cancer
28
cancer women
12
risk factors
8
cancer
8
women endometriosis
8
well-established ovarian
8
cancer risk
8
risk ovarian
8
ovarian
7
women
5

Similar Publications

Ovarian cancer is a deadly gynecological disease with frequent recurrence. Current treatments for patients include platinum-based therapy regimens with PARP inhibitors specific for HR-deficient high-grade serous ovarian cancers (HGSOCs). Despite initial effectiveness, patients inevitably develop disease progression as tumor cells acquire resistance.

View Article and Find Full Text PDF

Exploring miRNA profile associated with cisplatin resistance in ovarian cancer cells.

Biochem Biophys Rep

March 2025

Department of Molecular and Biotechnology, Atomic Energy Commission of Syria (AECS), Syria.

Ovarian cancer is a common and lethal malignancy among women, whereas chemoresistance is one of the major challenges to its treatment and prognosis. Chemoresistance is a multifactorial phenomenon, involving various mechanisms that collectively modify the cell's response to treatment. Among the changes that arise in cells after acquiring chemoresistance is miRNA dysregulation.

View Article and Find Full Text PDF

We recently reported on the development of a unique cancer-targeting peptide called NAF-1 (derived from CISD2/NAF-1). NAF-1 selectively permeates the plasma membrane (PM) of cancer cells, but not healthy cells, causing the activation of apoptotic and ferroptotic cell death pathways specifically in cancer cells. NAF-1 also targets and shrinks human breast and ovarian cancer tumors in a xenograft mice model system without any apparent side effects.

View Article and Find Full Text PDF

Ovarian cancer is the seventh most common lethal tumor among women in the world. FOXM1 is a transcription factor implicated in the initiation and progression of ovarian cancer by regulating key oncogenic genes. The role of regulatory regions in regulating the expression of FOXM1 in ovarian cancer is not completely clarified.

View Article and Find Full Text PDF

TWIST1 Regulates FOXM1/β-Catenin to Promote the Growth, Migration, and Invasion of Ovarian Cancer Cells by Activating MFAP2.

J Biochem Mol Toxicol

February 2025

Department of Gynecologic Oncology, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang, China.

TWIST1 is aberrantly expressed in ovarian cancer (OC). MFAP2 is a downstream target of TWIST1, and we previously found MFAP2 facilitated OC development by activating FOXM1/β-catenin. We planned to investigate the mechanisms of TWIST1 in OC.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!